FTC advances new theories in rare pharma challenge

Amgen is incentivised to use its control of several blockbuster medications to entrench Horizon Therapeutics' monopolies over gout and eye disease treatments, the Federal Trade Commission has alleged in suing to block the $27.8 billion merger.

Unlock unlimited access to all Global Competition Review content